Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV - Proetel, Ulrike; Müller, Martin Christian; Hanfstein, Benjamin; Kalmanti, Lida; Schreiber, Annette; Hofmann, Wolf-Karsten; Hehlmann, Rüdiger; Saußele, Susanne (Annals of hematology, 2014)
Gesehen am: 16.12.2015